T. Araki

Effects of vedolizumab in Japanese patients with Crohn’s disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses

T. Matsui, H. Ogata, T. Hibi, 2019, Journal of Gastroenterology.

Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study

T. Matsui, H. Ogata, T. Hibi, 2019, PloS one.

GPR40‐induced insulin secretion by the novel agonist TAK‐875: first clinical findings in patients with type 2 diabetes

K. Kaku, S. Hiroi, M. Hirayama, 2012, Diabetes, obesity & metabolism.

Randomized, Double-Blind, Dose-Ranging Study of TAK-875, a Novel GPR40 Agonist, in Japanese Patients With Inadequately Controlled Type 2 Diabetes

K. Kaku, Ryoji Yoshinaka, T. Araki, 2013, Diabetes Care.

Acid‐inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects ‐ a randomised open‐label cross‐over study

Y. Sakurai, A. Nishimura, H. Okamoto, 2015, Alimentary pharmacology & therapeutics.

Efficacy and Safety of Vonoprazan in Patients With Nonerosive Gastroesophageal Reflux Disease: A Randomized, Placebo-Controlled, Phase 3 Study

Y. Kinoshita, K. Iwakiri, T. Miyagi, 2019, Clinical and translational gastroenterology.